Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Tonix Pharmaceuticals Holding (TNXP) Invested Capital (2023 - 2025)

Tonix Pharmaceuticals Holding has reported Invested Capital over the past 3 years, most recently at $245.2 million for Q4 2025.

  • Quarterly results put Invested Capital at $245.2 million for Q4 2025, up 65.41% from a year ago — trailing twelve months through Dec 2025 was $245.2 million (up 65.41% YoY), and the annual figure for FY2025 was $245.2 million, up 65.41%.
  • Invested Capital for Q4 2025 was $245.2 million at Tonix Pharmaceuticals Holding, up from $231.1 million in the prior quarter.
  • Over the last five years, Invested Capital for TNXP hit a ceiling of $245.2 million in Q4 2025 and a floor of $49.3 million in Q2 2024.
  • Median Invested Capital over the past 3 years was $144.3 million (2023), compared with a mean of $146.9 million.
  • Biggest five-year swings in Invested Capital: tumbled 64.87% in 2024 and later soared 240.48% in 2025.
  • Tonix Pharmaceuticals Holding's Invested Capital stood at $116.5 million in 2023, then rose by 27.19% to $148.2 million in 2024, then soared by 65.41% to $245.2 million in 2025.
  • The last three reported values for Invested Capital were $245.2 million (Q4 2025), $231.1 million (Q3 2025), and $168.0 million (Q2 2025) per Business Quant data.